USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients

USV Pvt. Ltd, a leading drug manufacturer in the diabetes & cardiology segment, has announced the launch of the Liralin Range for the treatment of type 2 diabetes in Indian patients.

USV's Liralin Range is launched in 3 SKU forms: Liralin, Liralin DP & Liralin M. Liralin M will be introduced soon.

Liralin contains Linagliptin 5 mg, whereas Liralin DP is an FDC of Linagliptin 5 mg & Dapagliflozin 10 mg. Liralin M is an FDC containing Linagliptin 5 mg & Metformin 1000 mg

Liralin DP is available at INR 19.9/- per tablet, while Liralin is priced at INR 11.9/- per tablet.

Linagliptin has multiple clinical and safety advantages, making it potentially an evergreen OAD agent as monotherapy and in combination with other agents